{"id":201501,"date":"2026-08-13T15:05:41","date_gmt":"2026-08-13T09:35:41","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=201501"},"modified":"2026-08-13T15:05:43","modified_gmt":"2026-08-13T09:35:43","slug":"marksans-pharma-q1-results-fy27-pat-159-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/marksans-pharma-q1-results-fy27-pat-159-crore\/","title":{"rendered":"Marksans Pharma Q1 FY27 Results: Revenue Rs 840 Cr, PAT Rs 159 Cr and Key Highlights"},"content":{"rendered":"
<\/div>\n

Marksans Pharma Q1 FY27: Revenue Rs 840 Cr (+35.61% YoY). PAT Rs 159 Cr (+173.89% YoY). Results August 12, 2026. CMP Rs 309.50.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Marksans Pharma reported a 174% jump in net profit to Rs 159 crore in Q1 FY27, compared with Rs 58 crore in the same quarter last year. Revenue climbed 36% to Rs 840 crore during the June 2026 quarter, with gross profit expanding significantly to Rs 188 crore. The Marksans Pharma Q1 FY27 results reflect solid operating momentum within the Pharmaceuticals sector.<\/p>\n<\/div>\n

Marksans Pharma<\/a> Q1 FY27 results were declared on August 12, 2026, with the pharmaceuticals company reporting a net profit (PAT) of Rs 159 crore, up 173.89% from Rs 58 crore in Q1 FY26. The figures are on a consolidated basis for the quarter ended June 30, 2026.<\/p>\n

The June 2026 quarter saw sharp growth in Marksans Pharma’s revenue, which climbed 36% year on year to Rs 840 crore. Gross profit for the period stood at Rs 188 crore, up from Rs 77 crore a year earlier.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n